Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy

Bibliography

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer5(8),615–625 (2005).
  Medline CASGoogle Scholar
• 2  Gjerstorff MF, Kock K, Nielsen O, Ditzel HJ: MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Hum. Reprod.22(4),953–960 (2007).
  Medline CASGoogle Scholar
• 3  Koslowski M, Bell C, Seitz G et al.: Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res.64(17),5988–5993 (2004).
  Medline CASGoogle Scholar
• 4  Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev.188,22–32 (2002).
  Medline CASGoogle Scholar
• 5  Hofmann O, Caballero OL, Stevenson BJ et al.: Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA105(51),20422–20427 (2008).▪ Comprehensive survey of cancer germline antigen gene expression in normal tissues and cancer.
  Medline CASGoogle Scholar
• 6  Karpf AR: Cancer germline antigens. In: Encyclopedia of cancer (2nd Edition). Schwab M (Ed.). Springer-Verlag, Berlin, Germany, 478–479 (2008).
  Google Scholar
• 7  Almeida LG, Sakabe NJ, Deoliveira AR et al.: CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res.37(Database issue),D816–D819 (2009).
  Medline CASGoogle Scholar
• 8  Scanlan MJ, Simpson AJ, Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun.4,1 (2004).
  MedlineGoogle Scholar
• 9  Van Der Bruggen P, Traversari C, Chomez P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science254(5038),1643–1647 (1991).
  Medline CASGoogle Scholar
• 10  Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res.61(14),5544–5551 (2001).
  Medline CASGoogle Scholar
• 11  Smith IM, Glazer CA, Mithani SK et al.: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS ONE4(3),E4961 (2009).▪ Demonstrates that CG antigen genes are activated and hypomethylated in conjunction with BORIS expression in a subset of human tumors.
  MedlineGoogle Scholar
• 12  Glazer CA, Smith IM, Ochs MF et al.: Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS ONE4(12),E8189 (2009).
  MedlineGoogle Scholar
• 13  Odunsi K, Jungbluth AA, Stockert E et al.: NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res.63(18),6076–6083 (2003).
  Medline CASGoogle Scholar
• 14  Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR: Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin. Cancer Res.14(11),3283–3290 (2008).▪▪ Demonstrates that heterogeneous expression of CG antigens in individual tumors in vivo correlates with epigenetic states.
  Medline CASGoogle Scholar
• 15  Gjerstorff M, Burns JS, Nielsen O, Kassem M, Ditzel H: Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy. Am. J. Pathol.175(1),314–323 (2009).▪▪ Reveals mechanisms involved in CG antigen gene regulation in cancer stem cells.
  Medline CASGoogle Scholar
• 16  Karpf AR: A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics1(3),116–120 (2006).
  MedlineGoogle Scholar
• 17  Berger Sl, Kouzarides T, Shiekhattar R, Shilatifard A: An operational definition of epigenetics. Genes Dev.23(7),781–783 (2009).
  Medline CASGoogle Scholar
• 18  De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA93(14),7149–7153 (1996).
  Medline CASGoogle Scholar
• 19  De Smet C, Lurquin C, Lethe B, Martelange V, Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol.19(11),7327–7335 (1999).
  Medline CASGoogle Scholar
• 20  Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene21(35),5400–5413 (2002).
  Medline CASGoogle Scholar
• 21  Weber J, Salgaller M, Samid D et al.: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2´-deoxycytidine. Cancer Res.54(7),1766–1771 (1994).
  Medline CASGoogle Scholar
• 22  Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2´-deoxycytidine. Mol. Pharm.65(1),18–27 (2004).
  CASGoogle Scholar
• 23  Illingworth RS, Bird AP: CpG islands – ‘a rough guide’. FEBS Lett.583(11),1713–1720 (2009).
  Medline CASGoogle Scholar
• 24  Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene21(35),5496–5503 (2002).
  Medline CASGoogle Scholar
• 25  Wischnewski F, Friese O, Pantel K, Schwarzenbach H: Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol. Cancer Res.5(7),749–759 (2007).
  Medline CASGoogle Scholar
• 26  Morgan HD, Santos F, Green K, Dean W, Reik W: Epigenetic reprogramming in mammals. Hum. Mol. Genet.14(1),R47–R58 (2005).
  Medline CASGoogle Scholar
• 27  Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene20(24),3139–3155 (2001).
  Medline CASGoogle Scholar
• 28  James SR, Link PA, Karpf AR: Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3B. Oncogene25(52),6975–6985 (2006).
  Medline CASGoogle Scholar
• 29  Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun.7,21 (2007).
  MedlineGoogle Scholar
• 30  Loriot A, De Plaen E, Boon T, De Smet C: Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J. Biol. Chem.281(15),10118–10126 (2006).
  Medline CASGoogle Scholar
• 31  Karpf AR, Bai S, James SR, Mohler JL, Wilson EM: Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol. Cancer Res.7(4),523–535 (2009).▪ Reveals a mechanism by which activation of a CG antigen promotes a specific oncogenic phenotype: evolution to castration recurrent prostate cancer.
  Medline CASGoogle Scholar
• 32  Wischnewski F, Pantel K, Schwarzenbach H: Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res.4(5),339–349 (2006).
  Medline CASGoogle Scholar
• 33  Link PA, Gangisetty O, James SR et al.: Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol. Cancer Res.7(6),851–862 (2009).
  Medline CASGoogle Scholar
• 34  Jenuwein T, Allis CD: Translating the histone code. Science293(5532),1074–1080 (2001).
  Medline CASGoogle Scholar
• 35  Lin W, Dent SY: Functions of histone-modifying enzymes in development. Curr. Opin. Genet. Dev.16(2),137–142 (2006).
  Medline CASGoogle Scholar
• 36  Ellis L, Atadja PW, Johnstone RW: Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther.8(6),1409–1420 (2009).
  Medline CASGoogle Scholar
• 37  Wargo JA, Robbins PF, Li Y et al.: Recognition of NY-ESO-1⁺ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother.58(3),383–394 (2009).▪ Provides evidence that adoptive T-cell-transfer-based immunotherapy is augmented by epigenetic therapy.
  Medline CASGoogle Scholar
• 38  Weiser TS, Guo ZS, Ohnmacht GA et al.: Sequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother.24(2),151–161 (2001).
  Medline CASGoogle Scholar
• 39  Lachner M, O’Sullivan RJ, Jenuwein T: An epigenetic road map for histone lysine methylation. J. Cell. Sci.116(Pt 11),2117–2124 (2003).
  Medline CASGoogle Scholar
• 40  Tachibana M, Sugimoto K, Nozaki M et al.: G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev.16(14),1779–1791 (2002).
  Medline CASGoogle Scholar
• 41  Tachibana M, Ueda J, Fukuda M et al.: Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev.19(7),815–826 (2005).
  Medline CASGoogle Scholar
• 42  Dong KB, Maksakova IA, Mohn F et al.: DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity. EMBO J.27(20),2691–2701 (2008).
  Medline CASGoogle Scholar
• 43  Tachibana M, Matsumura Y, Fukuda M, Kimura H, Shinkai Y: G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J.27(20),2681–2690 (2008).
  Medline CASGoogle Scholar
• 44  Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q: Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol. Cancer Ther.8(12),3191–3202 (2009).
  Medline CASGoogle Scholar
• 45  Sigalotti L, Fratta E, Coral S et al.: Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2´-deoxycytidine. Cancer Res.64(24),9167–9171 (2004).
  Medline CASGoogle Scholar
• 46  Loriot A, Sterpin C, De Backer O, De Smet C: Mouse embryonic stem cells induce targeted DNA demethylation within human MAGE-A1 transgenes. Epigenetics3(1),38–42 (2008).
  MedlineGoogle Scholar
• 47  Costa FF, Le Blanc K, Brodin B: Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells25(3),707–711 (2007).
  Medline CASGoogle Scholar
• 48  Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B: Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res.65(6),2207–2215 (2005).
  Medline CASGoogle Scholar
• 49  Loriot A, Reister S, Parvizi GK, Lysy PA, De Smet C: DNA methylation-associated repression of cancer-germline genes in human embryonic and adult stem cells. Stem Cells27(4),822–824 (2009).
  Medline CASGoogle Scholar
• 50  Sigalotti L, Covre A, Zabierowski S et al.: Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell Physiol.215(2),287–291 (2008).
  Medline CASGoogle Scholar
• 51  Gedye C, Quirk J, Browning J et al.: Cancer/testis antigens can be immunological targets in clonogenic CD133⁺ melanoma cells. Cancer Immunol. Immunother.58(10),1635–1646 (2009).▪▪ Reports that CD133+ melanoma stem cells show enhanced CG antigen gene expression, which is further selected for by chemotherapy, and can be effectively targeted by NY-ESO-1-specific cytotoxic T lymphocytes.
  Medline CASGoogle Scholar
• 52  Yawata T, Nakai E, Park KC et al.: Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol. Carcinog. (2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 53  De Smet C, Courtois SJ, Faraoni I et al.: Involvement of two ETS binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics42(4),282–290 (1995).
  Medline CASGoogle Scholar
• 54  Serrano A, Garcia A, Abril E, Garrido F, Ruiz-Cabello F: Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int. J. Cancer68(4),464–470 (1996).
  Medline CASGoogle Scholar
• 55  Maier H, Colbert J, Fitzsimmons D, Clark DR, Hagman J: Activation of the early B-cell-specific MB-1 (IG-a) gene by PAX-5 is dependent on an unmethylated ETS binding site. Mol. Cell. Biol.23(6),1946–1960 (2003).
  Medline CASGoogle Scholar
• 56  Klenova EM, Morse HC III, Ohlsson R, Lobanenkov VV: The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin. Cancer Biol.12(5),399–414 (2002).
  Medline CASGoogle Scholar
• 57  Loukinov DI, Pugacheva E, Vatolin S et al.: BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc. Natl Acad. Sci. USA99(10),6806–6811 (2002).
  Medline CASGoogle Scholar
• 58  Hong JA, Kang Y, Abdullaev Z et al.: Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res.65(17),7763–7774 (2005).
  Medline CASGoogle Scholar
• 59  Vatolin S, Abdullaev Z, Pack SD et al.: Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res.65(17),7751–7762 (2005).▪ Implicates the CTCF paralog BORIS as a global regulator of CG antigen gene expression.
  Medline CASGoogle Scholar
• 60  Nguyen P, Bar-Sela G, Sun L et al.: BAT3 and SET1a form a complex with CTCFl/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol. Cell. Biol.28(21),6720–6729 (2008).
  Medline CASGoogle Scholar
• 61  Hoffmann MJ, Muller M, Engers R, Schulz WA: Epigenetic control of CTCFl/BORIS and OCT4 expression in urogenital malignancies. Biochem. Pharmacol.72(11),1577–1588 (2006).
  Medline CASGoogle Scholar
• 62  Rousseaux S, Khochbin S: New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators. Epigenomics1(1),153–161 (2009).
  CASGoogle Scholar
• 63  Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C: Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int. J. Cancer122(4),777–784 (2007).
  Google Scholar
• 64  Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol.20(6),1692–1703 (2002).
  Medline CASGoogle Scholar
• 65  Hoei-Hansen CE, Kraggerud SM, Abeler VM et al.: Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol. Cancer6,12 (2007).
  MedlineGoogle Scholar
• 66  Yang B, Wu J, Maddodi N, Ma Y, Setaluri V, Longley BJ: Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. J. Invest. Dermatol.127(9),2123–2128 (2007).
  Medline CASGoogle Scholar
• 67  Kondo T, Zhu X, Asa SL, Ezzat S: The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin. Cancer Res.13(16),4713–4720 (2007).
  Medline CASGoogle Scholar
• 68  Zhu X, Asa SL, Ezzat S: Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin. Cancer Res.14(7),1984–1996 (2008).▪ Illustrates how specific transcription factors and signal transduction molecules interact with epigenetic states to regulate CG antigen gene expression.
  Medline CASGoogle Scholar
• 69  Monte M, Simonatto M, Peche LY et al.: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA103(30),11160–11165 (2006).
  Medline CASGoogle Scholar
• 70  Yang B, O’Herrin SM, Wu J et al.: MAGE-A, mMAGE-B, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res.67(20),9954–9962 (2007).
  Medline CASGoogle Scholar
• 71  Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS: Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene26(30),4394–4403 (2007).
  Medline CASGoogle Scholar
• 72  Renaud S, Pugacheva EM, Delgado MD et al.: Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res.35(21),7372–7388 (2007).
  Medline CASGoogle Scholar
• 73  Bai S, Grossman G, Yuan L et al.: Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol. Hum. Reprod.14(2),107–116 (2008).
  Medline CASGoogle Scholar
• 74  Sabbatini P, Odunsi K: Immunologic approaches to ovarian cancer treatment. J. Clin. Oncol.25(20),2884–2893 (2007).
  Medline CASGoogle Scholar
• 75  Davis ID, Chen W, Jackson H et al.: Recombinant NY-ESO-1 protein with iscomatrix adjuvant induces broad integrated antibody and CD4⁺ and CD8⁺ T cell responses in humans. Proc. Natl Acad. Sci. USA101(29),10697–10702 (2004).
  Medline CASGoogle Scholar
• 76  Chen YT, Scanlan MJ, Sahin U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA94(5),1914–1918 (1997).
  Medline CASGoogle Scholar
• 77  Jager E, Nagata Y, Gnjatic S et al.: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA97(9),4760–4765 (2000).
  Medline CASGoogle Scholar
• 78  Stockert E, Jager E, Chen YT et al.: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med.187(8),1349–1354 (1998).
  Medline CASGoogle Scholar
• 79  Jager E, Chen YT, Drijfhout JW et al.: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med.187(2),265–270 (1998).
  Medline CASGoogle Scholar
• 80  Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M: Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin. Cancer Res.10(3),890–896 (2004).
  Medline CASGoogle Scholar
• 81  Sharma P, Gnjatic S, Jungbluth AA et al.: Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun.3,19 (2003).
  MedlineGoogle Scholar
• 82  Jager E, Jager D, Karbach J et al.: Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101–0103 and recognized by CD4⁺ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med.191(4),625–630 (2000).
  Medline CASGoogle Scholar
• 83  Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM: NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4⁺ T cells. Cancer Res.60(17),4946–4952 (2000).
  Medline CASGoogle Scholar
• 84  Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF: Identification of CD4⁺ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol.165(2),1153–1159 (2000).
  Medline CASGoogle Scholar
• 85  Zeng G, Li Y, El-Gamil M et al.: Generation of NY-ESO-1-specific CD4⁺ and CD8⁺ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res.62(13),3630–3635 (2002).
  Medline CASGoogle Scholar
• 86  Cheever MA, Allison JP, Ferris AS et al.: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res.15(17),5323–5337 (2009).
  MedlineGoogle Scholar
• 87  Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol.74,181–273 (2000).
  Medline CASGoogle Scholar
• 88  Hurwitz AA, Yu TF, Leach DR, Allison JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA95(17),10067–10071 (1998).
  Medline CASGoogle Scholar
• 89  Uyttenhove C, Pilotte L, Theate I et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med.9(10),1269–1274 (2003).
  Medline CASGoogle Scholar
• 90  Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25⁺CD4⁺ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol.163(10),5211–5218 (1999).
  Medline CASGoogle Scholar
• 91  Terabe M, Berzofsky JA: Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol.16(2),157–162 (2004).
  Medline CASGoogle Scholar
• 92  Terabe M, Matsui S, Noben-Trauth N et al.: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol.1(6),515–520 (2000).
  Medline CASGoogle Scholar
• 93  Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature429(6990),457–463 (2004).
  Medline CASGoogle Scholar
• 94  Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L: Epigenetic targets for immune intervention in human malignancies. Oncogene22(42),6484–6488 (2003).
  Medline CASGoogle Scholar
• 95  Coral S, Sigalotti L, Colizzi F et al.: Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J. Cell. Physiol.207(1),58–66 (2006).
  Medline CASGoogle Scholar
• 96  Sigalotti L, Altomonte M, Colizzi F et al.: 5-aza-2´-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood101(11),4644–4646; discussion 4645–4646 (2003).
  Medline CASGoogle Scholar
• 97  Schrump DS, Fischette MR, Nguyen DM et al.: Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res.12(19),5777–5785 (2006).▪▪ Demonstrates that decitabine therapy activates CG antigen gene expression and immune responses in cancer patients.
  Medline CASGoogle Scholar
• 98  Fonsatti E, Nicolay HJ, Sigalotti L et al.: Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2´-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res.13(11),3333–3338 (2007).
  Medline CASGoogle Scholar
• 99  Adair SJ, Hogan KT: Treatment of ovarian cancer cell lines with 5-aza-2´-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. Immunother.58(4),589–601 (2009).
  Medline CASGoogle Scholar
• 100  Lake RA, Robinson BW: Immunotherapy and chemotherapy – a practical partnership. Nat. Rev. Cancer5(5),397–405 (2005).
  Medline CASGoogle Scholar
• 101  Sfikakis PP, Gourgoulis GM, Moulopoulos LA, Kouvatseas G, Theofilopoulos AN, Dimopoulos MA: Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur. J. Clin. Invest.35(6),380–387 (2005).
  Medline CASGoogle Scholar
• 102  Matei DE, Nephew KP: Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol.116(2),195–201 (2010).
  Medline CASGoogle Scholar
• 103  Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol.23(10),2346–2357 (2005).
  Medline CASGoogle Scholar
• 104  Yee C, Riddell SR, Greenberg PD: Prospects for adoptive T cell therapy. Curr. Opin. Immunol.9(5),702–708 (1997).
  Medline CASGoogle Scholar
• 105  Riddell SR, Warren EH, Gavin MA et al.: Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones. Cancer J. Sci. Am.6(Suppl. 3),S250–S258 (2000).
  Google Scholar
• 106  Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314(5796),126–129 (2006).
  Medline CASGoogle Scholar